Company intelligence / Profile preview

Kyowa Pharmaceutical Industry

Osaka, Osaka-fu, Japankyowayakuhin.co.jp ↗

Ownership: Private
Employees: ~100
Development stage: Other

Overview

More than 300 products marketed in Japan, with ~60% in CNS. Recent launches include Bipresso® (extended release tablets for psychiatric disorders) and the AMEL generic CNS portfolio. Covers 94% of psychiatric hospitals in Japan.

Therapeutic areas: ImmunologyPsychiatryInfectious DiseasesGastroenterologyPulmonologyNeurology
Modalities: Small moleculeEnzyme
Industry: Biotech

Partnerships

Bora Pharmaceuticals (CDMO manufacturing for Japan market)Shionogi (product license transfer)Astellas (product licensing for Bipresso)neurocare group (JV for digital mental health in Japan)

Beyond the preview

Go deeper on Kyowa Pharmaceutical Industry.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kyowa Pharmaceutical Industry.